30-Second Takeaway
- Tighter GDM targets reduce LGA and cesarean rates but require more insulin without added serious adverse events.
- Real-time CGM modestly improves HbA1c and time-in-range versus SMBG in adults with type 2 diabetes.
- SARS-CoV-2 infection increases long-term type 2 diabetes risk, particularly after severe, unvaccinated illness.
- GLP-1 receptor agonists and semaglutide show vascular and possible colon cancer benefits but raise concern for NAION.
- SGLT2 inhibitors improve subclinical LV function, and diabetes duration tracks stepwise pancreatic cyst risk.
Week ending February 14, 2026
Tightening glycemic targets, leveraging CGM, and navigating GLP-1/SGLT2 benefits and risks in contemporary diabetes care
Tight GDM glycemic targets lower LGA and cesarean deliveries at the cost of more insulin
In this single-center RCT of 650 women with GDM, tighter glycemic targets reduced large-for-gestational-age births versus less tight control. Tight targets also lowered cesarean delivery rates and reduced maternal gestational weight gain. More women required insulin with tight control, but serious complications and maternal hypoglycemia rates remained low and similar between groups. These findings support tighter glycemic targets in GDM when insulin initiation and monitoring resources are available.
Real-time CGM modestly improves glycemia and self-management in adults with type 2 diabetes
This systematic review and meta-analysis of 11 RCTs compared real-time CGM with SMBG in adults with type 2 diabetes. Real-time CGM produced modest HbA1c reductions and improved time-in-range, with less time above and below target compared with SMBG. Glucose variability decreased and readiness for diabetes self-management improved, without clear benefits in broader cardiometabolic or psychosocial outcomes. Data support integrating real-time CGM for adults requiring intensive monitoring and behavioral adjustment rather than solely for long-term risk modification.
SARS-CoV-2 infection confers an 18% higher long-term risk of type 2 diabetes
This population-based cohort of over 2 million adults in British Columbia assessed incident type 2 diabetes after SARS-CoV-2 testing. Compared with test-negative individuals, those infected had an 18% higher diabetes risk over a median 874 days of follow-up. Risk rose progressively with COVID-19 severity, from ambulatory illness to hospitalization and intensive care. No excess diabetes risk was observed among vaccinated subgroups, and elevated risk persisted for up to 3 years before waning.
GLP-1 receptor agonists are associated with substantially lower colon cancer risk in RCTs
This systematic review and network meta-analysis pooled 17 RCTs including 36,415 adults treated with GLP-1 receptor agonists. GLP-1 RA use was associated with a markedly reduced colon cancer risk, with a pooled relative risk around one-third of comparators. Risks for colorectal carcinoma overall, rectal cancer, and other intestinal cancers appeared neutral. Subgroup analyses suggested longer treatment duration and lower baseline HbA1c, particularly with albiglutide and subcutaneous semaglutide, might maximize colon cancer risk reduction.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.